Ad
BCRX - BioCryst Pharmaceuticals Stock Trading
About | BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
Not available
Quote | BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
| Last: | $7.2092 |
|---|---|
| Change Percent: | -4.13% |
| Open: | $7.55 |
| Close: | $7.52 |
| High: | $7.64 |
| Low: | $7.18 |
| Volume: | 418,998 |
| Last Trade Date Time: | 09/28/2023 03:00:00 am |
News | BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
-
RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Institut national d'excellence en santé et services sociaux (INESSS) has issued a positive recommendation for Pr ORLADEYO ® (berotrals...
-
2023-08-31 03:30:52 ET Summary Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. The largest five stakes in the portfolio are Seagen, Incyte, BeiGene, ACADIA Pharmaceuticals, and Madrigal Pharmaceuticals, making up around 83% of the portfolio. Baker Brothe...
Message Board Posts | BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
| Subject | By | Source | When |
|---|---|---|---|
| whytestocks: $BCRX News Article - BioCryst Pharmaceuticals (BCRX) Q1 2023 Earnings Call Transcript | whytestocks | investorshangout | 05/03/2023 6:15:53 PM |
| whytestocks: $BCRX News Article - BioCryst Presents New Long-term and Real-world Data Demonstrating | whytestocks | investorshangout | 02/24/2023 1:35:47 PM |
| Huge buys in AH | ttubular | investorshub | 01/25/2023 11:01:34 PM |
| Why is this symbol now taking a digger | VivaLasVegas | investorshub | 12/14/2022 11:39:49 PM |
| whytestocks: $BCRX News Article - FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, | whytestocks | investorshangout | 08/31/2022 2:10:56 PM |
BioCryst Pharmaceuticals Inc. Company Name:
BCRX Stock Symbol:
NASDAQ Market:
BioCryst Pharmaceuticals Inc. Website:
Ad
-
RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Institut national d'excellence en santé et services sociaux (INESSS) has issued a positive recommendation for Pr ORLADEYO ® (berotrals...
-
2023-08-28 08:30:00 ET Growth stocks have lost momentum in August after a strong start to the year. The market is worried about the impact of a possible recession, high inflation, and high interest rates on the future earnings of companies. However, smart investors know that market downturn...
-
2023-08-03 14:30:28 ET Image source: The Motley Fool. BioCryst Pharmaceuticals (NASDAQ: BCRX) Q2 2023 Earnings Call Aug 03, 2023 , 8:30 a.m. ET Operator Continue reading For further details see: BioCryst Pharmaceuticals (BCRX) Q2 2023 Ear...